Search

Page Title

Clinical Trial Finder

Back to the Clinical Trial Finder

Anti-Inflammatory Completed with Results

Study to evaluate CB-280 in adults with cystic fibrosis and chronic Pseudomonas aeruginosa (Calithera CX-280-202 )

This study looked at the safety and tolerability of CB-280, an oral drug taken twice a day intended to treat infections in the lung and reduce inflammation. Multiple doses of the drug were tested in adults with cystic fibrosis and chronic Pseudomonas aeruginosa to find the best dose.

 This was a placebo-controlled study, meaning that some participants received CB-280 and others received a placebo. Researchers tested the safety and tolerability of CB-280 by monitoring for adverse events. This study enrolled adults with cystic fibrosis who have chronic Pseudomonas aeruginosa. 

Eligibility

See other primary eligibility criteria for more information.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40 to 90%

For more information about the results of this study and where it was conducted, visit ClinicalTrials.gov.

Other Primary Eligibility Criteria

Participants must have a history of at least two positive sputum cultures for Pseudomonas aeruginosa in the past year.

Study Results

  • What We Learned:

    This study completed in 2022.  As of February 2025 no results have been made public  and no additional studies in CF are currently planned. 

  • Primary Findings:

    Effectiveness:

    Safety:

  • Citation:

For current information about the overall development status of this drug, please check the Drug Development Pipeline.

Study Design

  • Study Type: ?more info

    Interventional

  • Randomized Study: ?more info

    Yes

  • Placebo Controlled: ?more info

    Yes

  • Length of Participation:

    2 months

  • Number of Study Visits:

    6

Additional Information

  • Phase: ?more info

    Phase One

  • Study Sponsor: ?more info

    Calithera Biosciences

  • Study Drugs:

    CB-280

Eligibility

See other primary eligibility criteria for more information.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40 to 90%

  • Pseudomonas Status:

    Positive Respiratory Cultures Required

For more information about the results of this study and where it was conducted, visit ClinicalTrials.gov.

Other Primary Eligibility Criteria

Participants must have a history of at least two positive sputum cultures for Pseudomonas aeruginosa in the past year.

CONTACT THE CLINICAL TRIAL NAVIGATOR

Get personalized assistance and answers to your clinical trial questions.

Learn More

Sign up for clinical trial alerts

Get email updates about clinical trials that matter to you.

Check the Drug Development Pipeline

We’re attacking CF from every angle. Learn about the status of CF drugs in development.

Learn More